Pitch for Investment

Latest Insights, Interviews, News, and Resources.

The latest news from UKI2S and our portfolio companies

Medication

Crescendo Biologics Launches New Strategy In Oncology Drug Discovery & Development

16th October 2015

Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics, has announced the launch of the Company’s new drug development strategy.
Alzheimer’s

Cytox Announces Participation In Insight Alzheimer’s Study

13th October 2015

Participation will aid comparison of SNP genotyping with biomarker status.
Chris Martin

States Can Provide Seed Capital To Spur Growth

9th October 2015

Read the thoughts of Chris Martin Non Executive Directors on the UKI2S Seed Advisory board in the Financial Times.
Synthace research

Dow AgroSciences, Synthace Research Collaboration to Accelerate Product Development Using High Tech Tools

2nd October 2015

Synthace and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE:DOW), today announce they have entered into a research collaboration.
Mike Romanos

UK Innovation & Science Seed Fund Appoints Mike Romanos As Venture Partner

28th September 2015

UK Innovation & Science Seed Fund, the UK government-backed fund dedicated to kick-starting promising technology companies with a focus on engineering biology.
Ikarovec

Genome Editing Techniques: The Science and the Ethics

24th September 2015

A group of UK research organisations, including the Wellcome Trust, have confirmed their support for genome editing techniques in preclinical human research.
Taking notes

Desktop Genetics Ltd Raises £1.37 Million GBP ($2.15M USD) Funding

24th September 2015

Desktop Genetics Ltd (“DTG” or “the Company”), a UK bioinformatics company aiming to revolutionize the way genetic researchers work, announced today that it has secured an investment of £1.37M GBP

Developing treatment for glaucoma

Quethera Announces Seed Financing To Develop Gene Therapy Aimed At Preventing Blindness In Glaucoma Patients

24th September 2015

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding.
Lab work

Engineering Biology Brings Hope for Chlamydia Vaccine

2nd September 2015

The cross-disciplinary field of engineering biology allows scientists to design and engineer organisms to carry out new roles…
Laptop in meeting

Institution Launches Fund To Help Bridge ‘Valley Of Death’ Between Research And Bringing Products To Market

2nd September 2015

The Institution of Mechanical Engineers’ £2mn Stephenson Fund to invest in innovative companies working in the field of mechanical engineering.
CS - Tokamak

Tokamak Energy Named as a Technology Pioneer by World Economic Forum

5th August 2015

Tokamak Energy has today been recognised by the World Economic Forum as one of the world’s most innovative businesses.

Cytox collaboration

Cytox And Affymetrix Form Strategic Partnership To Develop And Commercialize Blood-Based Genetic Assay For Alzheimer’s Disease Risk Assessment

21st July 2015

Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia…
Tokamak Energy

The New Shape of Fusion

22nd May 2015

ITER, the international fusion reactor being built in France, will stand 10 stories tall, weigh three times as much as the Eiffel Tower, and cost its seven international partners $18 billion or more.

ZuvaSyntha Merger

BioSyntha and ZuvaChem Announce a Merger and Financing to Form ZuvaSyntha Ltd

18th May 2015

Combining excellence in industrial biotechnology.
Steps

Taking Experiments from Lab to Market: Thoughts From SynBioBeta London

6th May 2015

One of the most satisfying things about working with early stage biotech ventures is helping start-ups execute on their ideas.
Using Public Money

What Did Budget 2015 Offer to Early Stage and Growth Businesses?

23rd March 2015

Much of the focus in the recent Budget has been around George Osborne’s one liners at the expense of the leader of the Opposition.
Taking notes

Finding the Funding for Synbio: SynBioBeta London

16th March 2015

Synthetic biology is arguably the enabling technology of the post-silicon age, and is opening up new markets with novel products and services.
Building

Sci-Tech Daresbury

24th February 2015

Sci-Tech Daresbury (the Daresbury Science and Innovation Campus), based in Cheshire in he northwest of the UK, is home to over 100 high-tech companies.
knowing what matters

UKI2S Forges Partnerships To Help Finance High Growth Companies

6th February 2015

One of the UK’s most innovative venture capital funds is to partner with two leading organisations to help finance and support high growth companies.
Seeing the World in Colour

Seeing the World in Colour: Spectral Edge

22nd December 2014

Spectral Edge, a start up funded by the UK Innovation & Science Seed Fund, has created Eyeteq, a technology that could make dramatic changes for the one in ten of the male population.
Civet Coffee

Civet Coffee Without the Civets

10th December 2014

At up to £60 a cup, kopi luwak is one of the rarest and most expensive kinds of coffee in the world – it is also one with perhaps the oddest source.
centrum norwich research park

Norwich Research Park: Supporting Science Research in East Anglia

25th November 2014

The Norwich Research Park, based in East Anglia, is one of the UK Innovation & Science Seed Fund’s four campus research partners.
Scientist at work

An Introduction To Engineering Biology

31st October 2014

Synthetic biology is a new and exciting cross-disciplinary field that combines engineering approaches and mindsets with chemistry, computing and biological research…
Autumn

Newsletter Autumn 2014

30th October 2014

Engineering Biology Companies Are Coming of Age.
UKI2S

© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.

Stay updated

UKI2S
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.